- U.S.-based drug innovator CNS Pharmaceuticals is enrolling patients in a global clinic trial to evaluate the performance of the company’s lead drug candidate, Berubicin, in fighting glioblastomas
- Glioblastoma is an incurable brain cancer that is aggressive in its progression and recurrence, leaving most patients with a life expectancy of less than a year after diagnosis
- CNS’s efforts to fill an unmet medical need arise from promise shown during Berubicin’s initial development by another company over 15 years ago, which included a small-scale human safety trial that produced a patient with no detectable cancer and others that saw tumor shrinkage and stable disease
- The FDA has granted Berubicin Fast Track and Orphan Drug status and enrollment for the current potentially pivotal global Phase 2 clinical trial is taking place in the United States, France, Spain and Switzerland
An incurable brain cancer known as glioblastoma multiforme (“GBM”) has drawn the attention of researchers throughout the world as the medical science industry races to fill an unmet need for an effective treatment.
While surgery is a standard procedure for removing cancerous GBM tumors, the tumors tend to regrow within a narrow margin of time because of the cancer’s capacity to infiltrate the surrounding tissues, preventing the surgeon from clearly identifying the boundaries between the tumor and the…
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.